baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Soc. Generale Call 260 AMGN 16.01.../ DE000SW8QVG3 /

2024-06-19 9:43:17 PM	Chg.-0.010	Bid9:50:36 PM	Ask9:50:36 PM	Underlying	Strike price	Expiration date	Option type
6.640EUR	-0.15%	- Bid Size: -	- Ask Size: -	Amgen Inc	260.00 USD	2026-01-16	Call

GlobeNewswire 06-19 Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

GlobeNewswire 06-18 CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Confere...

GlobeNewswire 06-17 CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

GlobeNewswire 06-17 FDA Approves Phase II Clinical Trial for Ruxoprubart in ANCA Associated Vasculitis (AAV) – a Chronic...

GlobeNewswire 06-17 Solid Power Appoints Renewables Industry Veteran Linda Heller as Chief Financial Officer

GlobeNewswire 06-05 Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

GlobeNewswire 05-30 Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affa...

TeleTrader 05-28 US markets turn to losses, Dow plunges 330 points

TeleTrader 05-28 Wall Street opens mostly higher as T+1 stock trading returns

GlobeNewswire 05-28 Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

GlobeNewswire 05-27 Samsung Bioepis Announces Oral Presentation on Switching Period Results for SB16, a Proposed Biosimi...

GlobeNewswire 05-23 Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...

GlobeNewswire 05-22 CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire 05-22 Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...

GlobeNewswire 05-21 Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

GlobeNewswire 05-21 Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a bios...

GlobeNewswire 05-21 COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer

TeleTrader 05-16 FDA approves Amgen's small cell lung cancer drug

GlobeNewswire 05-16 CytomX Therapeutics Announces New Employment Inducement Grants

GlobeNewswire 05-15 Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

GlobeNewswire 05-14 Accumulus Synergy Sponsors Revolutionary Healthcare Data Standard, Advancing Towards Global Dossier

GlobeNewswire 05-14 Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...

GlobeNewswire 05-13 TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 05-09 Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

GlobeNewswire 05-09 argenx Reports First Quarter 2024 Financial Results and Provides Business Update

Soc. Generale Call 260 AMGN 16.01.../ DE000SW8QVG3 /

If you wish to receive reply to your feedback, please provide your email address.